Figure 2From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerProgression free survival time for the ITT population of patients randomized to receive (red) Cilengitide (600 mg/m2) and gemcitabine (1000 mg/m2) or (blue) gemcitabine alone (1000 mg/m2).Back to article page